Australia markets open in 7 hours 28 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.98+0.53 (+2.10%)
As of 12:31PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.70B
Enterprise value 2.36B
Trailing P/E 27.96
Forward P/E 22.83
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.18
Price/book (mrq)6.63
Enterprise value/revenue 6.21
Enterprise value/EBITDA 17.52

Trading information

Stock price history

Beta (5Y monthly) 0.54
52-week change 315.27%
S&P500 52-week change 3-11.93%
52-week high 325.98
52-week low 315.83
50-day moving average 321.25
200-day moving average 321.08

Share statistics

Avg vol (3-month) 3881.82k
Avg vol (10-day) 3805.65k
Shares outstanding 5106.25M
Implied shares outstanding 6N/A
Float 886.7M
% held by insiders 110.92%
% held by institutions 177.95%
Shares short (14 June 2022) 418.17M
Short ratio (14 June 2022) 424.81
Short % of float (14 June 2022) 426.53%
Short % of shares outstanding (14 June 2022) 417.10%
Shares short (prior month 12 May 2022) 420.3M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 29.41%
Operating margin (ttm)34.61%

Management effectiveness

Return on assets (ttm)16.12%
Return on equity (ttm)24.35%

Income statement

Revenue (ttm)380.23M
Revenue per share (ttm)3.37
Quarterly revenue growth (yoy)17.90%
Gross profit (ttm)360.7M
EBITDA 132.71M
Net income avi to common (ttm)111.84M
Diluted EPS (ttm)0.97
Quarterly earnings growth (yoy)-2.80%

Balance sheet

Total cash (mrq)345.53M
Total cash per share (mrq)3.25
Total debt (mrq)2.82M
Total debt/equity (mrq)0.69
Current ratio (mrq)6.78
Book value per share (mrq)3.84

Cash flow statement

Operating cash flow (ttm)177.72M
Levered free cash flow (ttm)139.04M